<DOC>
	<DOCNO>NCT03031119</DOCNO>
	<brief_summary>Part A investigate safety , tolerability , PK PD PF-06835919 administer 14 day multiple ascend dose design . Part B ass effect PF-06835919 co-administration low high dos PK atorvastatin single cohort .</brief_summary>
	<brief_title>Multiple Ascending Dose DDI Study</brief_title>
	<detailed_description />
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Healthy male female ( nonchildbearing potential ) 18 55 year old Body Mass Index 17.5 30.5 Known hereditary fructose intolerance fructose malabsorption disorder ( Part A ) Statin intolerance ( Part B ) Unable consume high fructose syrupcontaining beverage meal unit ( Part A )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>nonalcoholic steatohepatitis</keyword>
</DOC>